%0 Journal Article
%T Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
%A Katja Lundgren
%A Matthew Brown
%A Silvia Pineda
%A Jack Cuzick
%A Janine Salter
%A Lila Zabaglo
%A Anthony Howell
%A Mitch Dowsett
%A G£¿ran Landberg
%A the TransATAC investigators
%J Breast Cancer Research
%D 2012
%I BioMed Central
%R 10.1186/bcr3161
%X To clarify these challenging and partly contrasting treatment predictive and prognostic links for cyclin D1 we analysed a large cohort of postmenopausal breast cancer patients randomised to receive either adjuvant anastrozole or tamoxifen, as part of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. The CCND1 amplification status and protein expression of cyclin D1 were assessed by chromogenic in situ hybridisation and immunohistochemistry, respectively, in 1,155 postmenopausal, oestrogen-receptor-positive breast cancer patients included in the TransATAC substudy.Amplification of CCND1 was observed in 8.7% of the tumours and was associated with increased risk of disease recurrence (hazard ratio = 1.61; 95% confidence interval, 1.08 to 2.41) after adjustment for other clinicopathological parameters. In contrast, nuclear expression of cyclin D1 protein was associated with decreased recurrence rate (hazard ratio = 0.6; 95% confidence interval, 0.39 to 0.92). The intensity of nuclear or cytoplasmic expression was not of prognostic value. There was no significant interaction between cyclin D1 status and treatment efficacy, ruling out any major detrimental effect of tamoxifen in CCND1-amplified postmenopausal breast cancer.In summary, CCND1 amplification and low nuclear expression of cyclin D1 predicted poor clinical outcome in postmenopausal breast cancer patients treated with either anastrozole or tamoxifen.Current Controlled Trials ISRCTN18233230.Hormone dependence is a fundamental hallmark of the majority of breast cancers, and tumour growth can be inhibited either by deprivation of circulating oestrogens or by antagonising the effect of these hormones on their receptors [1]. The selective oestrogen receptor (ER) modulator tamoxifen has long been the most commonly used adjuvant therapy for patients with advanced hormone-sensitive breast cancer [2]. In recent years, however, aromatase inhibitors have become an alternative treatment option for postmenopausa
%U http://breast-cancer-research.com/content/14/2/R57